Roche Holding AG Virtual Event at the 2022 ASCO Annual Meeting Focusing on the Oncology Pipeline Transcript
Ladies and gentlemen, welcome to Roche virtual event of the 2022 ASCO Annual Meeting focusing on the oncology pipeline. My name is Henrik, and I'm the technical operator for today's call.
Kindly note that the webinar is being recorded. (Operator Instructions) One last remark, if you would like to follow the presented slides in your end as well, please feel free to go to roche.com/investors to download the presentation.
At this time, it's my pleasure to introduce you to Bruno Eschli, Head of Investor Relations. Bruno, the stage is yours.
Thanks, Henrik. So welcome to our ASCO '22 event focusing on our late-stage data presented at the conference and on our early oncology pipelines for both pRED and gRED. Let me quickly take you through the agenda of today. Next slide, please.
Our first speaker, Elena Bernedo-Arzac, our Head of Oncology Therapeutics, will provide us with an update on our late-stage oncology pipeline. Our second speaker, Ginna Laport, Global Head of Hematology and Product Development in NHL and CLL, will take us
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |